Phase 2 Completed N=113 Treatment

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

Metastatic Androgen Independent Prostate Cancer

Source: ClinicalTrials.gov NCT00849290 ↗

Enrolled (actual)

113

Serious AEs

29.4%

Results posted

Oct 2010

Primary outcomePrimary: Safety of APC8015F by Review of Reported Adverse Events — 109 Participants

Summary

This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

Outcome Measures

Outcome	Result	p-value
PRIMARY Safety of APC8015F by Review of Reported Adverse Events	109	—

Eligibility Criteria

Inclusion Criteria

Objective disease progression
Subjects must have been enrolled in the APC-Placebo arm of D9902B (NCT00065442)

Exclusion Criteria

Infection requiring IV antibiotics
Treatment with anticancer interventions within 14 days prior to enrollment
Any medical condition which could compromise the study's objectives (discretion from sponsor)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00849290). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.